XML 129 R114.htm IDEA: XBRL DOCUMENT v3.26.1
SUPPLEMENTARY CONSOLIDATED FINANCIAL STATEMENT SCHEDULE VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year $ 520 $ 931 $ 160
Charges (Credits) to Costs and Expenses 100 (130) 819
Charged to Other Accounts (22) (6) 14
Deductions From Allowance Accounts (329) (275) (62)
Balance at End of Year 269 520 931
Current allowances 259 500 921
Provision for bad debts 100 (130) 819
North American Pharmaceutical      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Provision for bad debts   (206) 725
Allowance for credit loss, writeoff 483 237  
Allowances for credit losses      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year 472 877 114
Charges (Credits) to Costs and Expenses 100 (130) 819
Charged to Other Accounts (38) (2) 5
Deductions From Allowance Accounts (330) (273) (61)
Balance at End of Year 204 472 877
Other allowances      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year 48 54 46
Charges (Credits) to Costs and Expenses 0 0 0
Charged to Other Accounts 16 (4) 9
Deductions From Allowance Accounts 1 (2) (1)
Balance at End of Year 65 48 54
Written-off      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Deductions From Allowance Accounts (329) (275) (62)
Credited to other accounts and other      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Deductions From Allowance Accounts $ 0 $ 0 $ 0